Dexmedetomidine
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sedation
Conditions
Sedation, Respiration, Artificial, Length of Stay
Trial Timeline
Jan 1, 2007 → Jan 1, 2008
NCT ID
NCT00409344About Dexmedetomidine
Dexmedetomidine is a approved stage product being developed by Pfizer for Sedation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00409344. Target conditions include Sedation, Respiration, Artificial, Length of Stay.
What happened to similar drugs?
7 of 20 similar drugs in Sedation were approved
Approved (7) Terminated (1) Active (13)
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
🔄Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01606852 | Phase 1/2 | Completed |
| NCT01692210 | Pre-clinical | Completed |
| NCT01528891 | Phase 3 | Completed |
| NCT01378988 | Phase 2 | Completed |
| NCT01169571 | Pre-clinical | Completed |
| NCT00936377 | Pre-clinical | Completed |
| NCT00839605 | Pre-clinical | Completed |
| NCT00526760 | Phase 3 | Completed |
| NCT00409344 | Approved | Terminated |
Competing Products
20 competing products in Sedation